Fig. 5 | Mucosal Immunology

Fig. 5

From: The JAK inhibitor ruxolitinib reduces inflammation in an ILC3-independent model of innate immune colitis

Fig. 5

Therapeutic anti-Thy1.2 treatment reverses established colitis in TRAG mice. Anti-Thy1.2 (1 mg/mouse; i.p.) treatments were administered every 3 days beginning at 8 weeks of age for 21 days. (a) Disease activity showing clinical improvement in Thy1.2 treated TRAG mice. After treatment reduced colitis was evident by (b) gross morphology of the colon and (c) histology. Colonic LPLs were assessed for total numbers of (d) neutrophils and (e) inflammatory myeloid cells (for (a) two-way ANOVA with sidak multiple comparison, T-test for other data). *p < 0.05, **p < 0.01. Data represent of two independent experiments, mean ± SEM (n = 5 mice/group)

Back to article page